Key result
ESC/ERS guidelines redefine precapillary pulmonary hypertension as mPAP >20 mm Hg and PVR >2 WU.
The updated 2022 ESC/ERS guidelines lower the mPAP threshold to >20 mm Hg and introduce a PVR threshold of >2 WU for precapillary PH, aiming for earlier detection and management of pulmonary vascular disease.
May prompt earlier PH screening; leaves open prospective validation of revised thresholds.
Pulmonary hypertension (PH) is a pathophysiological manifestation of a heterogeneous group of diseases characterized by abnormally elevated pulmonary arterial pressures diagnosed on right heart catheterization. The 2022 European Society of Cardiology (ESC) and European Respiratory Society (ERS) Guidelines for the diagnosis and treatment of PH provides a new hemodynamic definition to define PH by lowering the threshold of the mean pulmonary artery pressure (mPAP) to 20 mm Hg. Precapillary PH is thus now defined as a mPAP >20 mm Hg together with a normal pulmonary artery wedge pressure (<15 mm Hg) and an increased pulmonary vascular resistance (>2 Wood Units). The ESC/ERS 2022 Guidelines also introduce a revised clinical classification of PH while retaining its previous distinction between the five groups according to the underlying pathophysiology.
No takes yet. Share an insight, caveat, or question.
Lechartier et al. (2023) conducted a review in Pulmonary Hypertension. The 2022 ESC/ERS Guidelines updated the hemodynamic definition of precapillary pulmonary hypertension to a mean pulmonary artery pressure >20 mm Hg and pulmonary vascular resistance >2 Wood Units.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: